Open Letter: Biopharma Leaders Call For Diversity Drive
An open letter signed by key figures in UK biopharma, calls on industry leaders, HR and recruitment organizations to increase diversity in sector boardrooms and C-suites, by facilitating the path of women and minorities to the top. They note that biopharma lags behind other industries and that all-male boards are associated with under-performance compared with mixed-gender boards of recently floated firms.
You may also be interested in...
Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.